Effect of proton-pump inhibitor therapy on serum chromogranin A level.
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background: The neuroendocrine marker, chromogranin A (CgA) increases during medium- or long-term proton-pump inhibitor (PPI) treatment. Aims: To analyze the effect of ultra-short-term and diverse dose of PPI therapy on serum CgA and gastrin levels and evaluate the effect of PPI treatment cessation. Patients and Methods: Fasting serum CgA and gastrin were determined in newly diagnosed gastroesophageal reflux disease (GERD) patients (n = 54) treated with diverse doses of PPI during a 28-day period, in patients treated with PPIs for at least 6 months (n = 42), and in subjects where PPI treatment could be stopped (n = 11). Results: A significant stepwise increase of CgA levels was observed after 5 days during the 28-day period treatment with all PPI doses. Gastrin increased significantly also in the standard and high-dose PPI subgroups. The most prominent increase of CgA was observed in the high-dose PPI subgroup. Serum CgA and gastrin were markedly elevated after 6 months of PPI treatment, and decreased significantly after 5 days of PPI discontinuation. Conclusions: Serum CgA increases significantly even after ultra-short-term (5 days) PPI therapy. After long-term treatment, 5-day cessation of PPI therapy is sufficient to decrease significantly both CgA and gastrin levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the start of a PPI resulted in a CgA increase of about 1.5-, 2.5-, and 3-fold after 5, 10, and 28 d of PPI treatment, respectively (10).”
From Effect of Short-Term Proton Pump Inhibitor Treatment and Its Discontinuation on Chromogranin A in Healthy Subjects (2012) · cites this paper as [10]
In the citing paper
“These findings are in line with the increase in CgA in patients with gastroesophageal reflux disease in whom the start of a PPI resulted in a CgA increase of about 1.5-, 2.5-, and 3-fold after 5, 10, and 28 d of PPI treatment, respectively (10).”
From Effect of Short-Term Proton Pump Inhibitor Treatment and Its Discontinuation on Chromogranin A in Healthy Subjects (2012) · cites this paper as [10]
Citations
Cites
1 retracted
Donnellan, C., Preston, C., Moayyedi, P., & Sharma, N. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003245.pub3 · Cited by 150
RetractedThe Chromogranin–Secretogranin Family
Taupenot, L., Harper, K. L., & O'Connor, D. T. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021405 · Cited by 819
Gastro-oesophageal reflux disease
Moayyedi, P., & Talley, N. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68932-0 · Cited by 426
Long-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and Safety
Klinkenberg-Knol, E. C., Festen, H. P. M., Jansen, J. B. M. J., Lamers, C. B. H. W., Nelis, F., Snel, P., Luckers, A., Dekkers, C. P. M., Havu, N., & Meuwissen, S. G. M. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-3-199408010-00001 · Cited by 422
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Reimer, C., Søndergaard, B., Hilsted, L., & Bytzer, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.058 · Cited by 356
Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum, H. L., Arnestad, J. S., Brenna, E., Eide, I., Syversen, U., & Sandvik, A. K. (1996) · Gut · doi:10.1136/gut.39.5.649 · Cited by 243
A comparison between three commercial kits for chromogranin A measurements
Stridsberg, M., Eriksson, B., Oberg, K., & Janson, E. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770337 · Cited by 202 · cited 1×
“CgA-RIA CT’s sensitivity was 67p, specificity 96p with a positive predictive value of 97p and a negative predictive value of 63p in a comparison between three commercial kits for CgA measurement by Stridsberg et al. [”
ResultGastrin-histamine sequence in the regulation of gastric acid secretion.
Waldum, H. L., Sandvik, A. K., Brenna, E., & Petersen, H. (1991) · Gut · doi:10.1136/gut.32.6.698 · Cited by 190 · cited 1×
“BackgroundGastrin, released from antral G cells, is a main regulator of gastric acid secretion; furthermore, it has not only stimulatory but also trophic effect on gastric mucosa, especially on neuroendocrine cells, the enterochromaffin-like cells (ECL) of the stomach [”
BackgroundDiagnostic and Therapeutic Use of Proton Pump Inhibitors in Non-Cardiac Chest Pain: A Metaanalysis
Cremonini, F., Wise, J., Moayyedi, P., & Talley, N. J. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41657.x · Cited by 163
Cited by
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Proton-pump inhibitors: understanding the complications and risks
Malfertheiner, P., Kandulski, A., & Venerito, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.117 · Cited by 297
S2k-Leitlinie Neuroendokrine Tumore: AWMF-Reg. 021-27
Authors, Collaborators:, Deutsche Gesellschaft für Gastroenterologie, V. U. S. (., (Patientenvertretung), N. N. T. (. E. V., (Patientenvertretung), B. S. N. T. E. V. (.-S., Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO), U. A. I. O. (. D. D. K. E. V., (DGAV), D. G. F. A. U. V. E. V., (DGCH), D. G. F. C., (DGEBV), D. G. F. E. U. B. V., (DGNM), D. G. F. N. E. V., et al. (2018) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0604-2924 · Cited by 180
Chromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
Gut, P., Czarnywojtek, A., Fischbach, J., Bączyk, M., Ziemnicka, K., Wrotkowska, E., Gryczyńska, M., & Ruchała, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.57577 · Cited by 144
“The PPI therapy may increase CgA concentration just 5 days after the first intake and leads to CgA 5–10 times higher than the upper reference range, results often seen in patients with early stage NET [12].”
BackgroundHvid‐Jensen, F., Pedersen, L. H., Funch-Jensen, P. M., & Drewes, A. M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12693 · Cited by 103
“The gastrin level may increase 5–10 fold during PPI therapy, and may have anti-apoptotic and proliferative effects that contribute to neoplasia.(30) This may increase the risk of gastrointestinal tumours.”
BackgroundProblems Associated with Deprescribing of Proton Pump Inhibitors
Helgadóttir, H., & Bjornsson, E. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215469 · Cited by 111
Diagnosis of Zollinger-Ellison syndrome: Increasingly difficult
Ito, T., Cadiot, G., & Jensen, R. T. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i39.5495 · Cited by 101
Metz, D. C., Cadiot, G., Poitras, P., Ito, T., & Jensen, R. T. (2017) · International Journal of Endocrine Oncology · doi:10.2217/ije-2017-0018 · Cited by 102
Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future
Herszényi, L., Bakucz, T., Barabás, L., & Tulassay, Z. (2019) · Digestive Diseases · doi:10.1159/000505204 · Cited by 63
Self-citationMosli, H. H., Dennis, A., Kocha, W., Asher, L. J., & Van Uum, S. H. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1548 · Cited by 59
“(10) suggested that PPI therapy should be discontinued for 5 d before measuring CgA.”
BackgroundWhen does proton pump inhibitor treatment become long term? A scoping review
Haastrup, P., Jarbøl, D. E., Thompson, W., Hansen, J. M., Søndergaard, J., & Rasmussen, S. (2021) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2020-000563 · Cited by 57
Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future
Komarnicki, P., Musiałkiewicz, J., Stańska, A., Maciejewski, A., Gut, P., Mastorakos, G. P., & Ruchała, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195542 · Cited by 45
Chu, S., & Schubert, M. L. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328358e5cc · Cited by 43
“However, it should be noted that CgA is elevated in patients with atrophic gastritis as well as those treated with PPIs for as short as 5 days [50].”
A concise, practical guide to diagnostic assessment for mast cell activation disease
Afrin, L. B., & Molderings, G. J. (2014) · World Journal of Hematology · doi:10.5315/wjh.v3.i1 · Cited by 37
Ito, T., Igarashi, H., & Jensen, R. T. (2012) · Pancreas · doi:10.1097/mpa.0b013e318249a92a · Cited by 38
Serum pancreastatin: The next predictive neuroendocrine tumor marker
Rustagi, S., Warner, R. R. P., & Divino, C. M. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23359 · Cited by 34
“[12] Various vasoactive substances released by the tumors have been identified and by measuring their levels, they can be used as biomarkers to detect and monitor the activity of carcinoid/NETs.”
BackgroundInfluentialChromogranina A i jej rola w patogenezie cukrzycy
Herold, Z., Doleschall, M., Kövesdi, A., Patócs, A., & Somogyi, A. (2018) · Endokrynologia Polska · doi:10.5603/ep.a2018.0052 · Cited by 39
Self-citationIt Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors
Tran, C. G., Sherman, S. K., Scott, A. T., Ear, P. H., Chandrasekharan, C., Bellizzi, A. M., Dillon, J. S., O’Dorisio, T. M., & Howe, J. R. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08784-0 · Cited by 26
Predictors of Gastrin Elevation Following Proton Pump Inhibitor Therapy
Helgadóttir, H., Lund, S. H., Gizurarson, S. S., Metz, D. C., & Bjornsson, E. S. (2019) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001200 · Cited by 25
The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin
Helgadóttir, H., Metz, D. C., Yang, Y., Rhim, A. D., & Bjornsson, E. S. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.09.021 · Cited by 24
Bech, P., Martin, N. M., Ramachandran, R., & Bloom, S. R. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213489670 · Cited by 25
Fisher, A. V., Lopez‐Aguiar, A. G., Rendell, V. R., Pokrzywa, C. J., Rocha, F. G., Kanji, Z. S., Poultsides, G. A., Makris, E. A., Dillhoff, M. E., Beal, E. W., et al. (2019) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-04080-1 · Cited by 21
Prognostic significance of Chromogranin A in small pancreatic neuroendocrine tumors
Raoof, M., Jutric, Z., Melstrom, L. G., Lee, B., Li, D., Warner, S. G., Fong, Y., & Singh, G. P. (2018) · Surgery · doi:10.1016/j.surg.2018.10.018 · Cited by 22
Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms
Corsello, A., di Filippo, L., Massironi, S., Sileo, F., Capuzzo, A. D., Gemma, M. F., Carlucci, C., Cusini, C., Colombo, B., Dallatomasina, A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196858 · Cited by 20
Matar, S., Malczewska, A., Öberg, K., Bodei, L., Aslanian, H. R., Lewczuk-Myślicka, A., Filosso, P. L., Suarez, A. L., Kolasińska, A. D., Roffinella, M., et al. (2019) · Neuroendocrinology · doi:10.1159/000500202 · Cited by 19
Gastroenteropancreatic Neuroendocrine Tumors
Strosberg, J. (2018) · Wiley eBooks · doi:10.1002/9781118592168.ch39 · Cited by 19
Mikkelsen, G., Åsberg, A., Hultström, M. E., Aasarød, K., & Hov, G. G. (2017) · The International Journal of Biological Markers · doi:10.5301/jbm.5000278 · Cited by 18
Salle, S. P., Provençal, M., & Bourdeau, I. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2020.09.011 · Cited by 17
Melcescu, E., Hogan, R. B., Brown, K., Boyd, S. A., Abell, T. L., & Koch, C. A. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.09.025 · Cited by 14
Herold, Z., Herold, M., Nagy, P., Patócs, A., Doleschall, M., & Somogyi, A. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13203 · Cited by 14
Self-citationGalasso, L., Vitale, F., Giansanti, G., Esposto, G., Borriello, R., Mignini, I., Nicoletti, A., Verme, L. Z. D., Gasbarrini, A., Ainora, M. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167814 · Cited by 13
“Elevated levels are not exclusive to neuroendocrine neoplasms and may be observed in several benign or unrelated pathological conditions, including atrophic gastritis, renal or hepatic dysfunction, chronic inflammatory diseases, and in patients taking proton pump inhibitors (PPIs) [60–62].”
Role of MicroRNAs in Neuroendocrine Prostate Cancer
Sreekumar, A., & Saini, S. (2022) · Non-Coding RNA · doi:10.3390/ncrna8020025 · Cited by 13
“Nonetheless, these markers are routinely high in patients taking proton pump inhibitors common in PCa therapy [101,102].”
BackgroundCao, H., Qu, R., Zhang, Z., Kong, X., Wang, S., Jiang, K., & Wang, B. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20133068 · Cited by 13
Kövesdi, A., Kurucz, P. A., Nyírő, G., Darvasi, O., Patócs, A., & Butz, H. (2020) · Cancers · doi:10.3390/cancers12092488 · Cited by 14
Self-citationEvaluation of a new immunoassay for chromogranin A measurement on the Kryptor system
van der Knaap, R. H. P., Kwekkeboom, D. J., Ramakers, C. R. B., & de Rijke, Y. B. (2015) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2015.03.002 · Cited by 14
Yazdanpanah, O., Surapaneni, S., Shanah, L., & Kabashneh, S. (2021) · Cureus · doi:10.7759/cureus.14006 · Cited by 13
Alpha‐gal syndrome—Food or drug allergy: A case report
Božan, M., Lazarević, V. V., Marković, I., Morović‐Vergles, J., & Mitrović, J. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7830 · Cited by 12
Presentation, diagnosis, and management of mast cell activation syndrome
Afrin, L. B. (2013) · Cited by 23
Clinical guidelines “Chronic diarrhea in adults”
Lazebnik, L. B., Sarsenbaeva, A. S., Avalueva, E. B., Oreshko, L. S., Sitkin, S. I., Голованова, Е. В., Туркина, С. В., Khlynova, O. V., Sagalova, O., & Мирончев, О. В. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-188-4-7-67 · Cited by 14
Helgadóttir, H., Lund, S. H., Gizurarson, S. S., Waldum, H. L., & Bjornsson, E. S. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1859610 · Cited by 11
Holmberg, D., Mattsson, F., Xie, S.-H., Ness‐Jensen, E., El‐Serag, H. B., & Lagergren, J. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01930-3 · Cited by 11
Clark, B., Steel, C. M., Vokes, J. R., Shan, J. R., Gedye, K. R., Lovett, A., & Sykes, B. W. (2023) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16795 · Cited by 10
Farinea, G., Calabrese, M., Carfì, F. M., Saporita, I., Poletto, S., Delcuratolo, M. D., Turco, F., Audisio, M., Stefano, F. R. D., Tucci, M., et al. (2024) · Cells · doi:10.3390/cells13161396 · Cited by 10
“However, their interpretation may be confounded by other medications and concurrent diseases [29–31].”
BackgroundPlasma chromogranin A after severe burn trauma
Lindahl, A. E., Low, A., Stridsberg, M., Sjöberg, F., Ekselius, L., & Gerdin, B. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.10.004 · Cited by 10
Yao, H., Wang, L., Li, H., Xu, S., Bai, Z., Wu, Y., Chen, H., Goyal, H., & Qi, X. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2008909 · Cited by 10
Andreasi, V., Partelli, S., Manzoni, M. F., Muffatti, F., Colombo, B., Corti, A., & Falconi, M. (2018) · Pancreatology · doi:10.1016/j.pan.2018.11.005 · Cited by 10
Boyce, M. J., van den Berg, F., Mitchell, T., Darwin, K. L. R., & Warrington, S. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2150-x · Cited by 11
Sundahl, N., Slycke, S. V., & Brusselaers, N. (2016) · Acta chirurgica Belgica · doi:10.1080/00015458.2016.1139838 · Cited by 8
Boyce, M. J., van den Berg, F., Mitchell, T., Darwin, K. L. R., & Warrington, S. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2241-3 · Cited by 8
Romano, E., Rinzivillo, M., Lamberti, G., Marasco, M., Esposito, G., Campana, D., & Panzuto, F. (2025) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-24-113 · Cited by 7
Platelet-Expressed Synaptophysin (pSyn) as Novel Biomarker in Neuroendocrine Malignancies
Hinterleitner, M., Sipos, B., Wagner, V., Grottenthaler, J. M., Lauer, U. M., Zender, L., & Hinterleitner, C. (2021) · Cancers · doi:10.3390/cancers13102286 · Cited by 7
“, proton pump inhibitors) [35], impaired kidney function [36], heart diseases [37], or rheumatoid diseases [38].”
BackgroundThe Impact of Sex on the Response to Proton Pump Inhibitor Treatment
Helgadóttir, H., & Bjornsson, E. S. (2023) · Pharmaceuticals · doi:10.3390/ph16121722 · Cited by 7
“Several studies have found higher gastrin levels in patients on higher PPI doses [21,53–55].”
BackgroundCurrent Medical Controversies in Zollinger–Ellison Syndrome
Jensen, R. T., Ramos-Álvarez, I., & Norton, J. A. (2025) · Biomedicines · doi:10.3390/biomedicines13123051 · Cited by 5
Circulating Tumor Markers in Patients with Neuroendocrine Tumors – a Clinical Perspective
Halfdanarson, T. R., Howe, J. R., Haraldsdóttir, S., & O’Dorisio, T. M. (2015) · International Journal of Endocrine Oncology · doi:10.2217/ije.14.38 · Cited by 5
Jung, D. H., Youn, Y. H., Jung, H., & Lee, K. J. (2025) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm24128 · Cited by 4
Kruljac, I., Vurnek, I., Maasberg, S., Kust, D., Blaslov, K., Davidović, B. L., Štefanović, M., Demirović, A., Bišćanin, A., Filipović-Čugura, J., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1592-6 · Cited by 4
VIPoma: a rare cause of diarrhea. A case report
Sánchez-Salazar, S. M., Torres-Alzate, S., Muñoz-Cortés, V. M., Barrera, C. A. B., Gutiérrez-Montoya, J. I., & Román-Gonzaléz, A. (2021) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v69n3.81603 · Cited by 4
Gastric neuroendocrine tumors: A review of pathology and updated roadmap to surgical management
Agathis, A. Z., Lopez-May, M., Brown, C. S., & Divino, C. M. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i9.108748 · Cited by 3
Andreasi, V., Partelli, S., Manzoni, M. F., Muffatti, F., di Filippo, L., Crippa, S., Corti, A., & Falconi, M. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01750-5 · Cited by 3
Bösch, F., Altendorf-Hofmann, A., Koliogiannis, V., Ilhan, H., Jacob, S., Pretzsch, E., Nölting, S., Werner, J. M., Klauschen, F., Auernhammer, C. J., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04119-6 · Cited by 3
Fan, D., Li, X., Yu, Y., Wang, X., Fang, J., & Huang, C. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2681 · Cited by 3
“Additionally, CgA levels can be affected by certain medi‑ cations, such as proton pump inhibitors, which can lead to false‑positive results (31,32).”
BackgroundHerold, Z., Nagy, P., Patócs, A., & Somogyi, A. (2015) · Orvosi Hetilap · doi:10.1556/oh.2015.30087 · Cited by 3
Self-citationMagnusson, M. K., Lasson, A., Stridsberg, M., Isaksson, S., Strid, H., & Öhman, L. (2018) · Cogent Medicine · doi:10.1080/2331205x.2018.1484602 · Cited by 3
“…et al., 2015) and elevated serum CgA levels can be detected during various conditions including treatment with proton pump inhibitors (PPIs) (Pregun et al., 2011), treatment with serotonin-norepinephrine reuptake inhibitors (Karger et al., 2014), renal failure (Hsiao, Mezger, & O’Connor,…”
BackgroundGastroenteropancreatic Neuroendocrine Tumors
Fisher, G. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-18890-0_16 · Cited by 3
Delayed Management of Zollinger-Ellison Syndrome in a Noncompliant Patient
Klimko, A., Plotogea, O., Constantinescu, A., & Constantinescu, G. (2020) · Cureus · doi:10.7759/cureus.8471 · Cited by 2
Yao, Q., Tong, Y., Peng, R., Liu, Z., & Li, Y. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2020.08.003 · Cited by 2
Kılıçkap, S., & Yalçın, Ş. (2015) · Springer eBooks · doi:10.1007/978-3-662-45215-8_29 · Cited by 2
Lam, S. K., & Lau, G. K. K. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002788 · Cited by 2
“Histological studies have shown that PPI lead to hypertrophy of parietal cells [66,104,113,114], but not to FGP [26,33,34].”
BackgroundChromogranin A in gastrinomas: Promises and pitfalls
Rehfeld, J. F. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.03.039 · Cited by 2
Malabu, U. H., Karamatic, R., Mahy, G., & Sangla, K. S. (2011) · Case Reports in Endocrinology · doi:10.1155/2011/342480 · Cited by 2
Kruljac, I., Vičić, I., Blaslov, K., Kolak, Z., Benković, M., Kust, D., Davidović, B. L., Tometić, G., Penavić, I., Dabelić, N., et al. (2018) · Neuroendocrinology · doi:10.1159/000492934 · Cited by 2
Evaluation of three commercially available ELISA kits for the determination of chromogranin A
Eeckhout, K., Cotthem, K. V., & Guerti, K. (2020) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2020.1830105 · Cited by 2
An unusual case of proton pump inhibitor induced hyperchromograninemia
Adu-Gyamfi, K. O., Gyamfi, R., & Patri, S. (2019) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2019.1682748 · Cited by 1
Neuroendocrine Tumors: Stomach
Wang, J., & Doherty, G. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-84737-1_26 · Cited by 1
Vokes, J. R., Gedye, K. R., Lovett, A. L., de Kantzow, M. C., Shan, R., Steel, C. M., & Sykes, B. W. (2024) · Animals · doi:10.3390/ani14202937 · Cited by 1
“With an increase in luminal pH during treatment with PPIs, there is a loss of somatostatin’s negative feedback on gastrin, leading to hypergastrinemia [5–9].”
BackgroundSzérum kromogranin A szint vizsgálata 2-es típusú cukorbetegségben
Herold, Z., Herold, M., Doleschall, M., & Somogyi, A. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.9 · Cited by 1
Glinicki, P., & Jeske, W. (2014) · Postępy Nauk Medycznych
A kromogranin-A szerepe diabetes mellitusban humán vizsgálatok és állatkísérletek alapján
Herold, Z., Patócs, A., Doleschall, M., & Somogyi, A. (2018) · Diabetologia Hungarica · doi:10.24121/dh.2018.5
Self-citationAdvances in the Diagnosis and Management of Gastrinoma
Finnerty, B. M., & Fahey, T. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66195-9.00019-4
Naf, E., Sw, G., Rma, I., Ayash, B., Raj, A.-A., Ame, A., & Wwa, S. (2019) · Biomedical Research-tokyo
Allergic contact dermatitis masquerading as carcinoid syndrome
Vigil, N. H., & Hamann, D. J. (2020) · Contact Dermatitis · doi:10.1111/cod.13729
Chromogranin A in diagnosis of pheochromocytoma (comparative analysis)
Yukina, M. Y., Karpova, P., Troshina, E. A., Platonova, N. M., & Beltsevich, D. G. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.04.200678
Neumann, T. (2021) · Refubium (Universitätsbibliothek der Freien Universität Berlin) · doi:10.17169/refubium-29555
Gawel, R. J., Zhang, Q., & Boigon, M. I. (2022) · Cureus · doi:10.7759/cureus.32079
Aktaş, B. Y., Kılıçkap, S., & Yalçın, Ş. (2024) · Springer eBooks · doi:10.1007/978-3-031-56968-5_29
Krčálová, E., Horáček, J., Sulková, S., Svilias, I., Hovorková, E., Nová, M., Ryba, M., Turková, L., Dvořák, P., Repák, R., et al. (2018) · Česká radiologie · doi:10.55095/cesradiol2018/006
Clarke, A., Cunningham, A., García‐Álvarez, A., Spurgeon, L. C., Morgan, R. D., Alonso, A. C., Hernando, J., Capdevila, J., Backen, A. C., Campana, L. G., et al. (2025) · Neuroendocrinology · doi:10.1159/000547192
“…NENs, but the utility of CgA and 5-HIAA is limited by significant variability of normal limits across laboratories or analytic methods and sampling confounders (e.g., fasting [19, 20], concomitant treatment with proton pump inhibitors, etc. [7, 21]), and there are no studies focussing on LC.”
Tepeš, M., Madžar, Z., Dušanić, D., Ćosić, V., Mikšić, B., Puljiz, M., Klapan, D., Bartulić, A., Flam, J., Madžar, T., et al. (2025) · Libri Oncologici Croatian Journal of Oncology · doi:10.20471/lo.2025.53.01.06
Böttcher, C. (2025) · Online Publication Service of Würzburg University (Würzburg University) · doi:10.25972/opus-40138
Hadjicosti, M. N., Papapostolou, A., Papoulas, M., Poulianiti, E., Christodoulidou, N., & Picolos, M. K. (2026) · Case Reports in Endocrinology · doi:10.1155/crie/6661577
“Pantoprazole, a proton pump inhibitor, has been established in literature to be a cause of increased chromogranin A levels [9, 10].”
Sztokfisz-Ignasiak, A., Owe-Larsson, M., Maj, M., Rytel, H., Shevchenko, K., Dabrowski, F. A., Laudański, P., Pater, M. M., Janiuk, I. R., & Malejczyk, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041567
“This may be exemplified by treatment with proton-pump inhibitors (PPIs), which have been reported to increase plasma and serum CgA concentrations in patients with dyspepsia and gastroesophageal reflux [44,45].”
Dascalescu, C. A., Herr, F. L., Ebner, R., Fusch, V., Schnitzer, M. L., Fabritius, M. P., Schmid‐Tannwald, C., Zacherl, M. J., Wenter, V., Brendel, M., et al. (2026) · Cancer Imaging · doi:10.1186/s40644-026-01113-w
“Variability in assay platforms, cutoffs, and confounding factors such as renal impairment or proton-pump inhibitor use may explain these discrepancies [43–47].”
D’Orazi, G., Monteonofrio, L., Verdina, A., & Garufi, A. (2026) · Cancers · doi:10.3390/cancers18182935
“Its circulating concentration can be substantially affected by non-tumor-related factors, including proton pump inhibitor (PPI) therapy [31], renal dysfunction [32], gastrointestinal conditions and other non-tumor related factors [30,33], which may lead to falsely elevated CgA levels and…”
Metadata
- Authors
- Pregun, I., Herszényi, L., Juhász, M., Miheller, P., Hritz, I., Patócs, A., Rácz, K., & Tulassay, Z.
- Affiliations
- Semmelweis University (HU)
- Venue
- Digestion
- Publisher
- S. Karger AG
- Published
- 2011
- Volume
- 84
- Issue
- 1
- Pages
- 22-28
- ISSN
- 0012-2823 (ISSN-L)
- 1421-9867
- OpenAlex
- W2028774131
- Cited by
- 89
- References
- 33
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 8 · 2019: 10 · 2018: 13 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 4 · 2012: 6
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Digestion (publishedVersion)
- PubMed (publishedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- proton pump inhibitors, chromogranin A, gastrin, gastroesophageal reflux disease, neuroendocrine markers, PPI discontinuation, long-term PPI therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Gastrins, Gastroesophageal Reflux, Humans, Male, Middle Aged, Prospective Studies, Time Factors, Helicobacter pylori, Helicobacter Infections, Chromogranin A, Proton Pump Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.